Beijing Balance Medical Technology (SHA:688198) said its all-comer interventional pulmonary valve and delivery system was accepted into the National Medical Products Administration's special review procedure for innovative medical devices.
The said medical device is specially designed for patients with complex congenital heart disease in need of a transcatheter artificial biological pulmonary valve replacement, according to a Jan. 4 filing with the Shanghai bourse.
Shares of the medical device manufacturer were down 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments